louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05168332: The Effect of Patellar Taping and Isometric Strength Training on Quadriceps Strength with Patellofemoral Pain Syndrome.
Official title: The Influence of Patellar Taping Combined with Isometric Strength Training on Pain, Muscle Strength, and Functional Performance in Individuals with Patellofemoral Pain Syndrome.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Patello Femoral Syndrome
Keywords: Patello-femoral pain syndrome
pain
strength
Maximum voluntary Isometric contraction (MVIC).
Lead sponsor: Majmaah University
Sponsor class: OTHER
First posted: 2021-12-23
Enrollment: 60
Sex: FEMALE
Minimum age (years): 25
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Experimental group Control group
Primary purpose: TREATMENT

Brief summary: Patellofemoral pain syndrome is one of the most common young adult female complaints, caused by changes in the patellofemoral joint's physical and biomechanical properties. This study compared the Short-term effects of patellar taping combined with isometric contraction of quadriceps muscle strengthening at 900 or 600 knee angles on quadriceps strength and functional performance in a female patient with patello-femoral pain syndrome (PFPS)

Detailed description: Quadriceps muscle strength Pain intensity Knee function

Eligibility criteria: Inclusion Criteria:

* knee pain for at least eight weeks that was aggravated by activities such as descending and ascending stairs, squatting, and running.
* knee pain with a positive J sign (lateral tilt of patella)
* more symptomatic and mal align knee included in case of bilateral involvement and a sign of patellar malalignment on the radiograph.

Exclusion Criteria:

* History of knee fracture
* Patella dislocation
* knee deformity (e.g., genu varum)
* Knee Flexion contracture
* Ligament/meniscal injuries,
* NSAID or intra-articular injection, or knee Osteo arthritis.

Primary outcomes:
measure: Quadriceps muscle strength
timeFrame: 6 weeks
measure: Pain intensity
timeFrame: 6 weeks
measure: Knee function
timeFrame: 6 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Al Majma'ah
country: Saudi Arabia
facility: Rehabilitation center, Majmaah University
state: Al Riyadh
Study officials:
affiliation: Associate Professor, Majmaah University
name: Shahnaz Hasan, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03726632: Causality of Poisoning of the Elderly: Prospective Study Based on Data From the Poison Control Centre of Bordeaux
Official title: Causality of Poisoning of the Elderly: Prospective Study Based on Data From the Poison Control Centre of Bordeaux Over 5 Months
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Intoxication
Keywords: Elderly
Intoxication
Poison Control centre
Poisoning
Accidental exposure
Prevention
Lead sponsor: University Hospital, Bordeaux
Sponsor class: OTHER
First posted: 2018-10-31
Enrollment: 122
Sex: ALL
Minimum age (years): 65
Maximum age (years): 99
Standard ages: OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All subjects aged 65 and over, victims of accidental or voluntary (excepted suicide) exposure of an agent (drug, household product, plant ...) and for who a call the Bordeaux Poison Control Centre has been called.

Brief summary: Elderly is often associated with social, physiological and psychic changes. However, no study has examined accidental poisoning-induced changes.

The objective of the study is to identify and analyze the various causes of potentially toxic accidental exposure of the elderly to determine preventable causes and propose prevention strategies.

Detailed description: Elderly is often associated with social, physiological and psychic changes. Many studies tried to demonstrate their influence in the genesis of pathological events such as falls or suicide of the elderly but none on the genesis of accidental poisoning.

However, poisoning in this age group is frequent and sometimes severe. In order to improve care of the elderly, it seems necessary to focus on potential toxic accidental exposure.

For this, Poison Control Centre of the University Hospital of Bordeaux has identified the causes over a period of 5 months (from 01 March to 31 July 2017) from calls to the centre.

Eligibility criteria: Inclusion Criteria:

* All subjects aged 65 and over,
* Victims of accidental exposure regardless of the agent (drug, household product, plant ...)
* Victims of voluntary exposure (out of suicidal behavior)
* And for which a call (notice, report) to the Poison Control Centre of Bordeaux has been recorded.
* Calling dates between March 1st and July 31st, even if the exhibition is prior to March 1st, 2017).

Exclusion Criteria:

* Suicide
* Calls for inquiries

Primary outcomes:
measure: Nature of the agent
timeFrame: Baseline
Secondary outcomes:
measure: Circumstance of the event
timeFrame: Baseline
measure: Exposition route of exposure
timeFrame: Baseline
measure: symptoms
timeFrame: Baseline
measure: Poisoning Severity
timeFrame: Baseline
measure: Death
timeFrame: Baseline
measure: Frailty status
timeFrame: Baseline
measure: packaging of the agent
timeFrame: Baseline
measure: Concomittant treatment
timeFrame: Baseline
Other outcomes:
Locations:
city: Bordeaux
country: France
facility: Centre Anti Poision du CHU de Bordeaux
Study officials:
References:
Clinical trial NCT03331432: Effects of Dietary Supplement Tauroursodeoxycholic Acid on Vascular Function
Official title: Targeting Endoplasmic Reticulum Stress to Correct Vascular Insulin Resistance and Glycemic Dysregulation
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Type 2 Diabetes Mellitus
Lead sponsor: University of Missouri-Columbia
Sponsor class: OTHER
First posted: 2017-11-06
Enrollment: 8
Sex: ALL
Minimum age (years): 20
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Intervention model description: Single-blinded randomized crossover study
Primary purpose: BASIC_SCIENCE

Brief summary: The purpose of the present study is to determine if use of dietary supplement tauroursodeoxycholic acid enhances insulin-stimulated leg blood flow and glucose disposal.

Detailed description: The notion that cellular stress lowers insulin-induced vasodilation is largely founded on ex vivo studies and experiments in rodents. However, it remains unknown if maintenance of cellular function with the use of dietary supplement tauroursodeoxycholic acid enhances vascular function in humans. The investigators test the hypothesis that daily administration of this dietary supplement enhances vascular function, particularly, insulin-stimulated leg blood flow and glucose disposal.

Eligibility criteria: Inclusion Criteria:

* Type 2 diabetes diagnosed by primary physician
* Body mass index less then 43 kg/m2

Exclusion Criteria:

* Recent weight gain or loss (\>5% body weight in the last 3 months)
* Pregnancy
* Consumption of \>14 alcoholic beverages per week
* Changes in the medication use or dose within the last 3 months
* Known cardiovascular or pulmonary disease
* Taking medication for advanced retinopathy or neuropathy
* Taking prescription anticoagulants
* Nicotine use

Primary outcomes:
measure: Blood flow
timeFrame: Once at 4 weeks after the start of placebo and once at 4 weeks after the start of tauroursodeoxycholic acid
measure: Vascular function
timeFrame: Once at 4 weeks after the start of placebo and once at 4 weeks after the start of tauroursodeoxycholic acid
measure: Insulin resistance
timeFrame: Once at 4 weeks after the start of placebo and once at 4 weeks after the start of tauroursodeoxycholic acid
measure: Glucose tolerance
timeFrame: Once at 4 weeks after the start of placebo and once at 4 weeks after the start of tauroursodeoxycholic acid
Secondary outcomes:
Other outcomes:
Locations:
city: Columbia
country: United States
facility: University of Missouri
state: Missouri
Study officials:
affiliation: University of Missouri-Columbia
name: Jaume Padilla, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03548532: Embryo Culture At a Constant Temperature of 36.6°C or 37.1°C
Official title: Embryo Culture At a Constant Temperature of 36.6°C or 37.1°C: a Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Temperature; Extreme, Exposure
Keywords: temperature
Lead sponsor: Universitair Ziekenhuis Brussel
Sponsor class: OTHER
First posted: 2018-06-07
Enrollment: 234
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Based on the randomisation list, patients fulfilling the inclusion criteria will be assigned to one of each arm. A total of 119 patients are needed in every arm in this superiority trial.
Primary purpose: DIAGNOSTIC

Brief summary: On the day of oocyte retrieval, participants will be randomized to stable culture at 37.1°C or 36.6°C with the ultimate aim of finding a difference in clincial pregnancies.

Detailed description: A previous study in our centre analysed stable embryo culture at 36.6°C and 37.1°C, on sibling oocytes. The primary aim was to analyse possible differneces in embryo development (utilization rate) up to day 5/6. In this study, the investigators found a high difference in clinical pregnancy rate between both groups (46.4% versus 77.4%). Since this study was not powered to find differences in clincial pregnancy rates between both groups, this RCT was especially powered as a superiority trial to find differences in clincial pregnancy rates between both groups. On the day of oocyte retrieval, patients will be allocated to culture at one of both temperatures.

Eligibility criteria: Inclusion Criteria:

* Day 5 transfer
* Single embryo transfer
* Only ejaculated sperm (fresh or frozen, autologous or heterologous)
* BMI \<35
* Age \<40 years
* Cycle rank \<3 for the current child
* Last ultrasound: 8 follicles of at least 12 mm
* At least 6 mature oocytes

Exclusion Criteria:

* IVF
* IVF versus ICSI
* Failed fertilization in previous cycle
* no previous cycle without embryo transfer
* No use of Ca ionophores for embryo quality or fertilization problems

Primary outcomes:
measure: Clinical pregnancy
timeFrame: 7 weeks
Secondary outcomes:
measure: Fertilization rate
timeFrame: 1 day
measure: embryo development/utilization rate
timeFrame: 6 days
measure: live birth rate of the fresh cycle
timeFrame: 43 weeks
measure: cumulative live birth rate per cycle
timeFrame: 104 weeks
Other outcomes:
Locations:
city: Brussels
country: Belgium
facility: Universitair Ziekenhuis Brussel
Study officials:
affiliation: UZBrussel
name: Greta Verheyen, PhD
role: STUDY_DIRECTOR
References:
Clinical trial NCT04344132: Pre- vs. Postoperative Scalp Block for Pain Control After Supratentorial Craniotomy
Official title: Pre- vs. Postoperative Scalp Block for Pain Control After Supratentorial Craniotomy
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Supratentorial Neoplasms
Lead sponsor: University of Roma La Sapienza
Sponsor class: OTHER
First posted: 2020-04-14
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Study was designed to evaluate optimal timing for selective scalp block in patients undergoing general anesthesia for supratentorial craniotomy.Pain score assessed by visual analog scale (VAS) preoperatively (baseline) and after extubation at 2, 6, 12 and 24 hours; time first request of a patient for rescue analgesia; intraoperative anesthetics and opioids consumption; awakening time; perioperative complications.


Eligibility criteria: Inclusion Criteria:

* Adult patients (\>18 years),
* presenting with supratentorial brain tumors scheduled for elective craniotomy under general anesthesia

Exclusion Criteria:

* history of allergic reactions on local anesthetics;
* ASA status ≥ 3;
* depressed consciousness in pre- or postoperative period;
* aphasia (as investigators were not able to obtain VAS score).

Primary outcomes:
measure: Visual Analogue Scale score at 24 h after surgery
timeFrame: up to 24 hours
Secondary outcomes:
measure: Visual Analogue Scale score at 0
timeFrame: Baseline
measure: Visual Analogue Scale score at 2 hours
timeFrame: up to 2 hours
measure: Visual Analogue Scale score at 6 hours
timeFrame: up to 6 hours
measure: Visual Analogue Scale score at 12 hours
timeFrame: up to 12 hours
measure: time first request of a patient for rescue analgesia
timeFrame: during surgery
measure: intraoperative anesthetics
timeFrame: during surgery time
measure: awakening time
timeFrame: time from the end of surgery to awekening
measure: changes in hemodynamics at mayfiled headfraom positioning
timeFrame: surgery
measure: changes in hemodynamics at mayfiled headfraom positioning
timeFrame: surgery
Other outcomes:
Locations:
Study officials:
References:
citation: Bebawy JF, Bilotta F, Koht A. A modified technique for auriculotemporal nerve blockade when performing selective scalp nerve block for craniotomy. J Neurosurg Anesthesiol. 2014 Jul;26(3):271-2. doi: 10.1097/ANA.0000000000000032. No abstract available.
citation: Tsaousi GG, Logan SW, Bilotta F. Postoperative Pain Control Following Craniotomy: A Systematic Review of Recent Clinical Literature. Pain Pract. 2017 Sep;17(7):968-981. doi: 10.1111/papr.12548. Epub 2017 Feb 23.
Clinical trial NCT02378337: Defining PET / CT Protocols With Optimized F18-FDG (Fluorodeoxyglucose) Dose, Focusing on Reduced Radiation Dose and Improved Image Quality
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Malignant Neoplasm of Breast
Hodgkin Disease
Non-Hodgkin Lymphoma, Follicular (Nodular)
Malignant Neoplasm of Bronchus and Lung
Malignant Neoplasm of Colon
Secondary Neoplasm Malignant and Unspecified Lymph Nodes
Malignant Melanoma of the Skin
Malignant Neoplasm of Small Intestine
Lead sponsor: Hospital Sao Rafael
Sponsor class: OTHER
First posted: 2015-03-04
Enrollment: 335
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: OTHER
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Will be observed all patients who perform PET / CT examinations, independent of clinical indication, in nuclear medicine at Hospital Sao Rafael. Those who show interest in participating in the study, will be provided free and informed consent form (ICF) for your appreciation. This evaluation will serve for analysis and quantification of PET-CT images.

Brief summary: Identify the best combination of predictive variables that influence ionizing radiation dose and improved image quality through analysis and quantification of PET-CT images in simulators and patients.


Eligibility criteria: Inclusion Criteria:

* Healthy volunteers;
* Both genders;
* Age over 18 years;
* Clinical indication for PET-CT scan.

Exclusion Criteria:

* Pregnant women;
* Patients who have lesions in the liver metabolically active whether primary or metastatic;
* Patients with movement difficulties.

Primary outcomes:
measure: Correlation of body weight with the variation coefficient (image noise).
timeFrame: 360 seconds
Secondary outcomes:
measure: Correlation of dose-regimen with the variation coefficient (image noise).
timeFrame: 360 seconds
measure: Correlation of acquisition protocol time with the variation coefficient (image noise).
timeFrame: 360 seconds
Other outcomes:
Locations:
city: Salvador
country: Brazil
facility: Hospital Sao Rafael
state: Bahia
Study officials:
affiliation: Hospital São Rafael
name: Milena BP Soares, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: Hospital São Rafael
name: Vinicius O Menezes, BSc
role: STUDY_CHAIR
affiliation: Hospital São Rafael
name: Marcos AD Machado, BSc
role: STUDY_CHAIR
affiliation: Hospital São Rafael
name: Cleiton C Queiroz, BSc
role: STUDY_CHAIR
affiliation: Fundacion Centro Diagnostico Nuclear
name: Mauro Namias, MSc
role: STUDY_CHAIR
References:
Clinical trial NCT06039137: The Effect of Switching the H1-antagonist Clemastine to Cetirizine in Premedication Regimens During Paclitaxel Treatment
Official title: The Effect of Switching the H1-antagonist Clemastine to Cetirizine in Premedication Regimens During Paclitaxel Treatment: 'The H1-SWITCH Study'
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Solid Tumor
Keywords: Paclitaxel
Allergic reaction
HSR
Chemotherapy
Premedication
Cancer
Oncology
Lead sponsor: Erasmus Medical Center
Sponsor class: OTHER
First posted: 2023-09-15
Enrollment: 395
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: OTHER
Sampling method: PROBABILITY_SAMPLE
Study population: Patients with solid tumors for whom paclitaxel-based chemotherapy is considered standard treatment will be eligible for this trial. Patients will be included from the outpatient population of the Erasmus MC in Rotterdam.

Brief summary: In this study the effect of substituting clemastine IV to cetirizine PO on the occurence of hypersensitivity reactions during paclitaxel chemotherapy will be investigated.

Detailed description: This is a single arm before-after study with a historic control cohort to evaluate the effect of a policy change (i.e. substitution of clemastine IV for cetirizine PO) regarding the premedication scheme on the incidence of HSR during paclitaxel based chemotherapy.

Eligibility criteria: Inclusion Criteria:

* Age ≥ 18 years;
* Planned treatment with regular paclitaxel-based chemotherapy for any indication and with any dose

Exclusion Criteria:

* Prior treatment with a paclitaxel-based regimen;
* Inability to orally ingest cetirizine

Primary outcomes:
measure: Clinically relevant hypersensitivity reactions
timeFrame: During the first six cycles of paclitaxel treatment (the length of one cycle of paclitaxel treatment varies but is typically 7-21 days, depending on standard of care protocol).
Secondary outcomes:
measure: Hypersensitivity reactions
timeFrame: During the first six cycles of paclitaxel treatment (the length of one cycle of paclitaxel treatment varies but is typically 7-21 days, depending on standard of care protocol).
measure: The difference in the number of paclitaxel dosages until first occurrence of hypersensitivity reactions
timeFrame: During the first six cycles of paclitaxel treatment (the length of one cycle of paclitaxel treatment varies but is typically 7-21 days, depending on standard of care protocol).
measure: The cumulative dose of paclitaxel (mg/m2) administered prior to the moment of hypersensitivity reaction
timeFrame: During the first six cycles of paclitaxel treatment (the length of one cycle of paclitaxel treatment varies but is typically 7-21 days, depending on standard of care protocol).
Other outcomes:
Locations:
city: Rotterdam
country: Netherlands
facility: Erasmus University Medical Center
state: Zuid-Holland
Study officials:
affiliation: Erasmus Medical Center
name: Roelof van Leeuwen, PharmD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01559337: Nerve Transfer for Finger Sensory Reconstruction With Dorsal Branch of the Digital Nerve
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Sensory Restoration of the Reconstructed Finger Pulps
Cold Intolerance of the Reconstructed Finger
Pain of the Reconstructed Finger
Keywords: defect
dorsal branch of the proper digital nerve
proper digital nerve
nerve transfer
finger sensory reconstruction
Lead sponsor: The Second Hospital of Tangshan
Sponsor class: OTHER
First posted: 2012-03-21
Enrollment: 17
Sex: ALL
Minimum age (years): 15
Maximum age (years): 50
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: A proper digital nerve (PDN) defect causes partial or complete sensory loss of the finger pulp, which results in functional disability.The dorsal branch of the PDN can be transferred for reconstruction of such nerve defects.In this study, the investigators modified the Lesavoy et al' technique and evaluated the efficacy of dorsal sensory branch transfer for PDN defects. For comparison, the investigators collected a consecutive series of 32 patients with finger PDN defects treated using a traditional sural nerve graft from February 2005 to October 2008.


Eligibility criteria: Inclusion Criteria:

1. Finger PDN defects proximal to the proximal interphalangeal joint
2. Single or two PDN defects
3. PDN defects longer than 1 cm.

Exclusion Criteria:

1. PDN defects less than 1 cm
2. Concomitant injuries to the multiple dorsal sensory branches that preclude their use as nerve donor sites
3. Thumb PDN defects.

Primary outcomes:
measure: static 2-point discrimination (2PD) test
timeFrame: 26 months
Secondary outcomes:
measure: self-administered Cold Intolerance Severity Score (CISS) questionnaire
timeFrame: 26 months
Other outcomes:
Locations:
city: Tangshan
country: China
facility: Ethetic Committee of Tangshan
state: Hebei
Study officials:
affiliation: Chinese PLA General Hospital
name: Peifu Tang, MD.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03033537: Intracavernosal Injection of Papaverine/Verapamil Versus Papaverine/Phentolamine in Erectile Dysfunction
Official title: Intracavernosal Injection of Papaverine/Verapamil Versus Papaverine/Phentolamine in Erectile Dysfunction: A Pilot Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Erectile Dysfunction
Lead sponsor: Adam International Hospital
Sponsor class: OTHER
First posted: 2017-01-27
Enrollment: 20
Sex: MALE
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: no
Observational model: CASE_CROSSOVER
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Males complaining of erectile dysfunction

Brief summary: Introduction: Erectile dysfunction is a common condition with a significant effect on quality of life. Verapamil is calcium channel blocker of the phenyl alkylamine class which relaxes the tone of the smooth muscles lining blood vessels, leading to their dilatation.

Detailed description: Objective: Evaluating the effect of intracavernosal injection of (Papaverine + Verapamil) and comparing it with (Papaverine + Phentolamine) in patients with erectile dysfunction.

Patients and methods: Each one of the 20 erectile dysfunction patients was subjected to intracavernosal injection with (30mg Papaverine + 1mg Phentolamine), where penile duplex \& clinical evaluation was carried out followed by a wash out interval of 2 weeks after which each patient was subjected to the exact previous procedures using (30 mg Papaverine + 5 mg Verapamil).

Keywords: Erectile dysfunction - Intracavernosal injection - Penile duplex - Phentolamine - Verapamil.

Eligibility criteria: Inclusion Criteria:

* Married male patients suffering from erectile dysfunction and scheduled for intracavernosal injection.

Exclusion Criteria:

* Responders to PDE5-inhibitors; congenital or acquired penile anomalies; uncontrolled medical conditions or known hypersensitivity to verapamil; Peyronie's disease and any known bleeding or coagulation disorders.

Primary outcomes:
measure: IIEF5
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References: